In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

Currently, chemotherapy remains the standard treatment for first-and second-line
management of small cell lung cancer (SCLC). Immunotherapy has made progress in the …

Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination …

Angiogenesis has always been the topic of major scientific interest in the field of malignant
tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by …

Abstract Treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth
factor receptor (EGFR) activating mutation with EGFR-TKIs has achieved great success, yet …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

Although nutrient-starvation therapies can elicit strong anti-tumor effects in multiple
carcinomas, it has been convincingly demonstrated that cancer cells exploit the tumor …

The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …

Angiogenesis is a double-edged sword; it is a mechanism that defines the boundary
between health and disease. In spite of its central role in physiological homeostasis, it …